english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Cannabidiol (Epidyolex°) in certain severe forms of childhood epilepsy: an option to consider, but liver function must be monitored

FEATURED REVIEW Cannabidiol (Epidyolex°) has been granted marketing authorisation in the European Union for patients aged 2 years and older with Lennox-Gastaut syndrome or Dravet syndrome, in combination with antiepileptic treatment including at least clobazam. How do Prescrire's editors rate this treatment in this situation?
Full text (3 pages) available for download by subscribers.
1 September 2020

In the September issue of Prescrire International. VEGF inhibitors: arterial aneurysm and dissection

FREE DOWNLOAD Drugs that target vascular endothelial growth factor (VEGF) inhibit angiogenesis and are mainly used to treat diseases involving vascular proliferation, in particular cancer and certain eye conditions (by intravitreal administration). They can provoke cardiovascular disorders such as hypertension, heart failure and arterial or venous thromboembolic events.
Full text available for free download.
1 September 2020

Evidence required: for covid-19 too

EDITORIALAside from the covid-19 epidemic's many major public-health and economic consequences around the world, it has also raised questions for many people about drug evaluation and the need for evidence before using a drug to treat patients.
1 September 2020

Mild asthma: adapt treatment according to patients’ needs

An inhaled beta-2 agonist as needed, possibly combined  with an as-needed or continuous inhaled corticosteroid.
1 September 2020

Priapism: urgent medical attention required

Priapism, an erection lasting several hours, needs to be diagnosed quickly in order to prevent possibly irreversible erectile dysfunction. It is often caused by medications.
1 September 2020

Drug shortages: a source of errors and adverse events, which should be reported

Drug shortages did not begin with the covid-19 epidemic. Some shortages cause serious harm to patients. Healthcare professionals and patients should report any adverse events related to drug shortages to the competent authorities.
1 September 2020

Covid-19 : Follow Prescrire's independent, evidence-based analysis of the pandemic

 COVID-19  Prescrire's editors are publishing an ongoing series of news updates featuring independent analysis of developments related to the covid-19 pandemic. Useful and practical information, to help healthcare professionals gain a clear and balanced view.
1 September 2020

Hydroxychloroquine in covid-19: no proven efficacy, including in less severe forms of the disease

 NEWS UPDATE  The detailed results of four comparative trials of hydroxychloroquine in patients with covid-19 were released in late July 2020: two trials in patients hospitalised for covid-19, and two others in patients who were not hospitalised and had milder forms of the disease.
24 July 2020

"Top Texts of 2020", from the editors of Prescrire International

1 August 2020

Covid-19: remdesivir (Veklury°) authorised in the European Union, yet much remains unknown or uncertain

 NEWS UPDATE  The antiviral drug remdesivir was authorised in the European Union in early July 2020 for the treatment of certain adults and adolescents with severe covid-19 requiring supplemental oxygen. It was only granted conditional authorisation, because the data submitted were incomplete on many fronts. The drug company needs to resolve many uncertainties surrounding remdesivir's adverse effects and efficacy.
13 July 2020

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90